PH12014500997B1 - 3,4-di-substituted pyridine compound, methods of using and compositions comprising the same - Google Patents

3,4-di-substituted pyridine compound, methods of using and compositions comprising the same

Info

Publication number
PH12014500997B1
PH12014500997B1 PH12014500997A PH12014500997A PH12014500997B1 PH 12014500997 B1 PH12014500997 B1 PH 12014500997B1 PH 12014500997 A PH12014500997 A PH 12014500997A PH 12014500997 A PH12014500997 A PH 12014500997A PH 12014500997 B1 PH12014500997 B1 PH 12014500997B1
Authority
PH
Philippines
Prior art keywords
compositions
methods
same
cyanonaphthalen
pyridin
Prior art date
Application number
PH12014500997A
Other languages
English (en)
Other versions
PH12014500997A1 (en
Inventor
Li-Tain Yeh
Barry D Quart
Original Assignee
Ardea Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ardea Biosciences Inc filed Critical Ardea Biosciences Inc
Publication of PH12014500997A1 publication Critical patent/PH12014500997A1/en
Publication of PH12014500997B1 publication Critical patent/PH12014500997B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PH12014500997A 2011-11-03 2014-05-02 3,4-di-substituted pyridine compound, methods of using and compositions comprising the same PH12014500997B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161555450P 2011-11-03 2011-11-03
US201261616363P 2012-03-27 2012-03-27
PCT/US2012/063415 WO2013067425A1 (en) 2011-11-03 2012-11-02 3,4-di-substituted pyridine compound, methods of using and compositions comprising the same

Publications (2)

Publication Number Publication Date
PH12014500997A1 PH12014500997A1 (en) 2014-08-04
PH12014500997B1 true PH12014500997B1 (en) 2014-08-04

Family

ID=47178362

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12014500997A PH12014500997B1 (en) 2011-11-03 2014-05-02 3,4-di-substituted pyridine compound, methods of using and compositions comprising the same

Country Status (21)

Country Link
US (2) US10047050B2 (enExample)
EP (2) EP3501520A1 (enExample)
JP (1) JP6025853B2 (enExample)
KR (1) KR101988066B1 (enExample)
CN (2) CN104023723B (enExample)
AU (1) AU2012332154B2 (enExample)
BR (1) BR112014010495A2 (enExample)
CA (1) CA2852490A1 (enExample)
DK (1) DK2776028T3 (enExample)
EA (1) EA026101B1 (enExample)
ES (1) ES2704233T3 (enExample)
HU (1) HUE040625T2 (enExample)
IL (1) IL232105A (enExample)
MX (1) MX352904B (enExample)
MY (1) MY180138A (enExample)
PH (1) PH12014500997B1 (enExample)
PL (1) PL2776028T3 (enExample)
SG (1) SG11201402016PA (enExample)
UA (1) UA114304C2 (enExample)
WO (1) WO2013067425A1 (enExample)
ZA (1) ZA201402795B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR081930A1 (es) * 2010-06-16 2012-10-31 Ardea Biosciences Inc Compuestos de tioacetato
ES2704233T3 (es) 2011-11-03 2019-03-15 Ardea Biosciences Inc Compuesto de piridina 3,4-di-sustituido, procedimientos de uso y composiciones que comprenden el mismo
CN105439946B (zh) * 2014-08-13 2018-02-02 益方生物科技（上海）有限公司 羧酸化合物及其制备方法和用途
CN104292124B (zh) * 2014-09-27 2016-01-20 张远强 硝基苯基取代的萘环丁二酸酰胺衍生物、其制备方法及用途
CN104311452B (zh) * 2014-09-27 2016-01-06 张远强 腈基萘环的丁二酸酰胺衍生物、其制备方法及用途
WO2017028762A1 (zh) * 2015-08-14 2017-02-23 广东东阳光药业有限公司 一种萘环化合物的晶型
JP6976946B2 (ja) * 2015-12-08 2021-12-08 アーディア・バイオサイエンシーズ・インコーポレイテッドArdea Biosciences, Inc. 生理活性の強い、ｕｒａｔ１のインヒビターを含む医薬組成物
CN105884807A (zh) * 2016-04-26 2016-08-24 昆药集团股份有限公司 硼酸频那醇酯衍生物的制备方法、硫代乙酸盐化合物的制备方法
CN106117130A (zh) * 2016-06-28 2016-11-16 昆药集团股份有限公司 一种2‑((3‑(4‑氰基萘‑1‑基)吡啶‑4‑基)硫基)‑2‑甲基丙酸的晶型及其制备方法和药物组合物
CN114315715B (zh) * 2020-09-29 2024-02-20 杭州中美华东制药有限公司 一类urat1抑制剂及其制备方法与应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6054310B2 (ja) 1979-02-21 1985-11-29 三井東圧化学株式会社 ピリダジン誘導体と農園芸用殺菌剤
US4889868A (en) 1984-12-20 1989-12-26 Rorer Pharmaceutical Corporation Bis-imidazolinoamino derivatives as antiallergy compounds
US5051442A (en) 1990-04-25 1991-09-24 Merrell Dow Pharmaceuticals Inc. 3-indolyl thioacetate derivatives and NMDA receptor antagonistic use thereof
SG86971A1 (en) 1990-11-30 2002-03-19 Teijin Ltd 2-arylthiazole derivatives and pharmaceutical composition thereof
US5405873A (en) 1992-09-10 1995-04-11 Banyu Pharmaceutical Co., Ltd. Substituted acetamide derivatives
US5344651A (en) 1993-07-23 1994-09-06 The Procter & Gamble Company Cyproterone acetate thioacetate
AU2395095A (en) 1994-04-29 1995-11-29 G.D. Searle & Co. Method of using (h+/k+) atpase inhibitors as antiviral agents
US6017925A (en) 1997-01-17 2000-01-25 Merck & Co., Inc. Integrin antagonists
WO2001091796A2 (en) * 2000-06-01 2001-12-06 Guilford Pharmaceuticals Inc. Methods, compounds and compositions for treating gout
GB0108339D0 (en) 2001-04-03 2001-05-23 Syngenta Participations Ag Organics compounds
JP3824899B2 (ja) * 2001-09-21 2006-09-20 株式会社ヒューマンセルシステムズ 腎臓及び胎盤型尿酸トランスポーターとその遺伝子
WO2007050087A1 (en) 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
ATE540677T1 (de) 2004-08-25 2012-01-15 Ardea Biosciences Inc S-triazolyl alpha mercaptoacetanilide als hemmer der reversen transkriptase von hiv
GB0422057D0 (en) 2004-10-05 2004-11-03 Astrazeneca Ab Novel compounds
US20070099970A1 (en) 2005-08-19 2007-05-03 Mackerell Alexander Immunomodulatory compounds that target and inhibit the pY'binding site of tyrosene kinase p56 LCK SH2 domain
US20090131384A1 (en) 2006-03-22 2009-05-21 Syndexa Pharmaceuticals Corporation Compounds and methods for treatment of disorders associated with er stress
EP2061760A1 (en) 2006-09-07 2009-05-27 Amgen, Inc Benzo-fused compounds for use in treating metabolic disorders
EP1939181A1 (en) 2006-12-27 2008-07-02 sanofi-aventis Heteroaryl-substituted carboxamides and use thereof for the stimulation of the expression of NO synthase
WO2009070740A2 (en) 2007-11-27 2009-06-04 Ardea Biosciences Inc. Novel compounds and compositions and methods of use
CN102014898B (zh) * 2008-04-30 2013-01-23 维尔斯达医疗公司 用于减少尿酸的四唑化合物
KR101294872B1 (ko) * 2008-09-04 2013-08-08 아디아 바이오사이언스즈 인크. 요산 수치를 조절하기 위한 화합물, 조성물 및 이들의 사용 방법
US8173690B2 (en) 2008-09-04 2012-05-08 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
CA2760940A1 (en) 2009-05-20 2010-11-25 Ardea Biosciences, Inc. Methods of modulating uric acid levels
EP2432774A4 (en) 2009-05-20 2013-01-02 Ardea Biosciences Inc COMPOUNDS, COMPOSITIONS AND METHODS FOR MODULATING URIC ACID RATES
WO2011044140A1 (en) 2009-10-05 2011-04-14 Catabasis Pharmaceuticals, Inc. Substituted thioacetic acid salicylate derivatives and their uses
MX2012007925A (es) 2010-01-08 2012-08-03 Ardea Biosciences Inc Formas polimorficas, cristalinas y de mesofase de 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-ilti o)acetato de sodio, y usos de las mismas.
WO2011126852A2 (en) * 2010-03-30 2011-10-13 Ardea Biosciences, Inc. Treatment of gout
PL2582683T3 (pl) 2010-06-15 2018-08-31 Ardea Biosciences, Inc. Leczenie dny moczanowej i hiperurykemii
AR081930A1 (es) * 2010-06-16 2012-10-31 Ardea Biosciences Inc Compuestos de tioacetato
BR112012032193A2 (pt) 2010-06-16 2019-09-24 Ardea Biosciences Inc composto, composiçoes e métodos de uso de feniltioacetato
ES2704233T3 (es) 2011-11-03 2019-03-15 Ardea Biosciences Inc Compuesto de piridina 3,4-di-sustituido, procedimientos de uso y composiciones que comprenden el mismo
JP6976946B2 (ja) * 2015-12-08 2021-12-08 アーディア・バイオサイエンシーズ・インコーポレイテッドArdea Biosciences, Inc. 生理活性の強い、ｕｒａｔ１のインヒビターを含む医薬組成物

Also Published As

Publication number Publication date
CN104023723A (zh) 2014-09-03
SG11201402016PA (en) 2014-05-29
MY180138A (en) 2020-11-23
CN104023723B (zh) 2017-05-31
ES2704233T3 (es) 2019-03-15
JP2014532726A (ja) 2014-12-08
WO2013067425A1 (en) 2013-05-10
US20190135756A1 (en) 2019-05-09
CN106963761A (zh) 2017-07-21
NZ623857A (en) 2016-08-26
KR101988066B1 (ko) 2019-09-27
EA026101B1 (ru) 2017-03-31
EA201490795A1 (ru) 2014-09-30
UA114304C2 (uk) 2017-05-25
AU2012332154A1 (en) 2014-05-01
AU2012332154B2 (en) 2016-11-17
MX2014005343A (es) 2014-09-08
MX352904B (es) 2017-12-13
PH12014500997A1 (en) 2014-08-04
JP6025853B2 (ja) 2016-11-16
EP3501520A1 (en) 2019-06-26
IL232105A (en) 2017-05-29
HUE040625T2 (hu) 2019-03-28
BR112014010495A2 (pt) 2017-04-25
US20140256748A1 (en) 2014-09-11
KR20140095078A (ko) 2014-07-31
US10047050B2 (en) 2018-08-14
EP2776028B1 (en) 2018-10-17
PL2776028T3 (pl) 2019-03-29
DK2776028T3 (en) 2019-02-04
IL232105A0 (en) 2014-05-28
ZA201402795B (en) 2019-09-25
CA2852490A1 (en) 2013-05-10
US10570095B2 (en) 2020-02-25
EP2776028A1 (en) 2014-09-17
HK1198929A1 (en) 2015-06-19

Similar Documents

Publication Publication Date Title
PH12014500997A1 (en) 3,4-di-substituted pyridine compound, methods of using and compositions comprising the same
UA107115C2 (uk) Тіоацетатні похідіні піридину, композиція на їх основі та їх застосування
TN2010000237A1 (en) Novel compounds and compositions and methods of use
WO2011159840A3 (en) Phenylthioacetate compounds, compositions and methods of use
WO2010135530A3 (en) Compounds, compositions and methods for modulating uric acid levels
WO2010028190A3 (en) Compounds, compositions and methods of using same for modulating uric acid levels
AU2018253580A1 (en) Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
NO20081482L (no) Delta- og epsilon-krystallformer for imatinibmesylat
EA201300669A1 (ru) Замещенные 1-бензилциклоалкилкарбоновые кислоты и их применение
TN2011000437A1 (en) Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof
WO2007101864A3 (en) Compounds that modulate ppar activity, their preparation and use
WO2010093727A8 (en) Quinazolinones as prolyl hydroxylase inhibitors
EA201000007A1 (ru) Производные индазоламида
BR112014009910A2 (pt) formulações de sal de meglumina de ácido 1-(5,6-dicloro-1h-benzo[d]imidazol-2-il)-1h-pirazol-4-carboxílico
MX354981B (es) Medicamento para tratamiento terapeutico y/o mejoramiento de sepsis.
MX342119B (es) 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
MX2013002121A (es) Quinolina-3-carboxamidas sustituidas como moduladores de kcnq2/3.
MX2013002208A (es) Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.
MY146403A (en) F, g, h, i and k crystal forms of imatinib mesylate
NZ712540A (en) Phenyl derivative having s1p2 antagonistic activity
EA201200764A1 (ru) Производные хиназолина
MX2010008586A (es) Amidas de acido 3-(4-fluorofenil)-3-hidroxi-2-amino-propionico y compuestos relacionados que tienen actividad analgesica.
EP1888782A4 (en) MODULATION OF STAT-6 EXPRESSION FOR THE TREATMENT OF HYPERREACTIVITY OF AIRWAYS
MX2013011561A (es) Compuestos de benzodioxepina y benzodioxina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.
MX2012007158A (es) Derivados de peroxidos de dibenzoilo, metodo de preparacion de los mismos, composiciones cosmeticas o dermatologicas que los contienen.